Top 5 4th Quarter Trades of Lipe & Dalton

Lipe & Dalton recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.

The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.

109 SOUTH WARREN STREET SYRACUSE, NY 13202

As of the latest 13F report, the guru’s equity portfolio contained 100 stocks valued at a total of $174.00Mil. The top holdings were AAPL(6.43%), ABBV(3.86%), and GS(3.75%).

According to GuruFocus data, these were Lipe & Dalton’s top five trades of the quarter.

Moderna Inc


The guru established a new position worth 14,644 shares in NAS:MRNA, giving the stock a 1.51% weight in the equity portfolio. Shares traded for an average price of $163.51 during the quarter.

On 02/04/2023, Moderna Inc traded for a price of $173.25 per share and a market cap of $66.56Bil. The stock has returned 5.67% over the past year.

GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 3 out of 10.

In terms of valuation, Moderna Inc has a price-earnings ratio of 6.27, a price-book ratio of 3.73, a EV-to-Ebitda ratio of 4.41 and a price-sales ratio of 3.58.

The price-to-GF Value ratio is 0.04, earning the stock a GF Value rank of 2.

Amedisys Inc


The guru sold out of their 22,952-share investment in NAS:AMED. Previously, the stock had a 1.39% weight in the equity portfolio. Shares traded for an average price of $90.16 during the quarter.

On 02/04/2023, Amedisys Inc traded for a price of $92.14 per share and a market cap of $2.99Bil. The stock has returned -30.66% over the past year.

GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 7 out of 10.

In terms of valuation, Amedisys Inc has a price-earnings ratio of 24.84, a price-book ratio of 2.95, a price-earnings-to-growth (PEG) ratio of 0.69, a EV-to-Ebitda ratio of 14.16 and a price-sales ratio of 1.36.

The price-to-GF Value ratio is 0.46, earning the stock a GF Value rank of 4.

Brookfield Asset Management Ltd


The guru established a new position worth 34,042 shares in NYSE:BAM, giving the stock a 0.5600000000000001% weight in the equity portfolio. Shares traded for an average price of $30.09 during the quarter.

On 02/04/2023, Brookfield Asset Management Ltd traded for a price of $33.7 per share and a market cap of $13.92Bil. The stock has returned 0.00% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 1 out of 10.

In terms of valuation, Brookfield Asset Management Ltd has a price-earnings ratio of 34.35, a price-book ratio of 2.03, a EV-to-Ebitda ratio of 13.37 and a price-sales ratio of 16.06.

Paramount Global


The guru sold out of their 44,445-share investment in NAS:PARA. Previously, the stock had a 0.53% weight in the equity portfolio. Shares traded for an average price of $18.4 during the quarter.

On 02/04/2023, Paramount Global traded for a price of $24.6 per share and a market cap of $16.11Bil. The stock has returned -22.67% over the past year.

GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 9 out of 10.

In terms of valuation, Paramount Global has a price-earnings ratio of 5.21, a price-book ratio of 0.70, a price-earnings-to-growth (PEG) ratio of 1.17, a EV-to-Ebitda ratio of 6.03 and a price-sales ratio of 0.55.

The price-to-GF Value ratio is 0.74, earning the stock a GF Value rank of 10.

Baxter International Inc


Lipe & Dalton reduced their investment in NYSE:BAX by 4,487 shares. The trade had a 0.15% impact on the equity portfolio. During the quarter, the stock traded for an average price of $53.71.

On 02/04/2023, Baxter International Inc traded for a price of $46.68 per share and a market cap of $23.53Bil. The stock has returned -44.45% over the past year.

GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 8 out of 10.

In terms of valuation, Baxter International Inc has a price-book ratio of 4.25, a EV-to-Ebitda ratio of -63.70 and a price-sales ratio of 1.61.

The price-to-GF Value ratio is 0.44, earning the stock a GF Value rank of 4.


Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.

When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.

Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!

This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.